Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 15/20 | 0.53 |
| ▸ | DRD2 | P14416 | 13/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758237 | 0.85 | NPC1 (0.76) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL17712729 | 0.84 | HDAC3 (0.69) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL20840889 | 0.83 | NPC1 (0.60) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL4385569 | 0.82 | DRD2 (0.71) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL18758357 | 0.81 | NPC1 (0.58) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL17713086 | 0.80 | NPC1 (0.56) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL378553 | 0.80 | DRD3 (0.54) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL17712975 | 0.79 | NPC1 (0.56) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL17712844 | 0.79 | HPGD (0.58) | NPC1RAB9AMEN1CYP1A2CYP2C19 | |
| SCHEMBL17713006 | 0.79 | NPC1 (0.55) | NPC1RAB9AMEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| CN-101291669-B | Use of azabicyclo hexane derivatives | GLAXO GROUP LTD | 2012-09-26 | — | — | CN | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| EP-2060570-B1 | Azabicyclo[3.1.0] hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| CN-101291669-A | Use of azabicyclo hexane derivatives | GLAXO GROUP LTD (GB) | 2008-10-22 | — | — | CN | disclosed |
| EP-1917013-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| CN-1946714-A | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | CN | disclosed |
| EP-1758890-A1 | 7-PYRAZOLYLBENZAZEPINES HAVING AFFINITY FOR D3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1751163-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005123717-A1 | 7-PYRAZOLYLBENZAZEPINES HAVING AFFINITY FOR D3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005118549-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | NPC1 2412/4885RAB9A 1474/4885MEN1 3416/4885 |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | DRD3, HTR3C, GRIN3A | NPC1 2170/4885RAB9A 1955/4885MEN1 3873/4885 |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | NPC1 943/4885RAB9A 1989/4885MEN1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.